Efavirenz to Nevirapine Switch and Low-Density Lipoprotein (LDL)-Dyslipidemia

Inclusion Criteria: * HIV-1 infected adults, who were receiving antiretroviral therapy including efavirenz for at least 6 months * plasma HIV RNA\<400 cp/ml during the previous 4 months on 2 occasions 14 days apart * Severe dyslipidemia with Low-Density Lipoprotein cholesterol (LDL-c) \>3.4 mmol/L in the presence of at least one of the 3 following coronary heart disease (CHD) risk factors: age\>45 among males or age\>55 among females, hypertension, current smoking, family history of CHD * Low-Density Lipoprotein cholesterol (LDL-c)\>4.1 mmol/L regardless of CHD risk factors. Exclusion Criteria: * Protease inhibitors use within the previous 6 months, * Prior exposure to nevirapine * Asparate aminotransferase (AST) or alanine aminotransferase (ALT) \>2.5N if hepatitis virus B or C were negative * AST or ALT\>1.25N if hepatitis virus B or C were positive * Fasting glycemia\>1.26g/L, * Current CHD * Triglycerides\>4.6 mmol/L * Introduction of lipid lowering drugs, corticoïds, retinoïds and betablockers within the previous 3 months.